Trienbio announced on the 10th that it will intensify its research and development focus on PDRN, exosomes, and next-generation delivery systems like hybrid oleosomes, aiming to penetrate the global cosmetic ingredient market more effectively. This strategic shift comes in response to a clear trend observed at in-cosmetics Korea 2026, where global brands and buyers expressed a growing demand for scientifically validated materials backed by rigorous data and differentiated bio-technologies. Such market changes signal a pivotal transition in the cosmetic ingredients sector.

In this evolving landscape, Trienbio emphasizes its commitment to plant-derived PDRN, positioning it as a cornerstone bio-material crucial for regeneration and anti-aging. There is considerable interest in PDRN's sourcing, manufacturing technology, quality control, and efficacy validation. This heightened scrutiny underscores the commercial necessity for ingredient providers to not only supply PDRN but also to substantiate its claims with comprehensive scientific evidence to gain traction in global markets.

To address these complexities, Trienbio is expanding its research into plant-derived PDRN, ensuring safety and sustainability while accumulating scientifically conclusive data that reinforces the credibility of its bio-material offerings. The firm’s commitment to developing a new PDRN platform leveraging diverse plant resources reflects a robust portfolio strategy aimed at enhancing product lines and meeting elevated consumer expectations regarding efficacy verification.

Exosomes remain a critical focus for Trienbio, applying cellular information transfer mechanisms to create next-generation functional materials. Particularly, plant-derived exosomes are recognized for their environmentally friendly and scalable characteristics. Trienbio is actively researching various plant-based exosomes to enhance functionalities such as skin calming, regeneration, and anti-aging, aligning with customer product concepts and bespoke material developments.

One of the most anticipated technologies introduced at the expo is Trienbio’s hybrid oleosome platform, which utilizes the natural oil storage structure found in plant seeds, merging biocompatibility with stability. This innovative delivery system aims to distinguish itself from existing carriers through specialized functional ingredient encapsulation technology. Despite being relatively novel, the high level of interest and inquiries surrounding this new delivery system indicates its potential for growth and market acceptance.

Trienbio plans to go beyond merely launching new materials, focusing instead on developing high-value platforms that integrate bio-technologies with delivery systems. The company's strategy includes strengthening scientific validation processes through efficacy mechanism studies and human application tests from the early stages of ingredient development, aiming to establish itself as a trusted tech-centric player in the global market.

The rapid transformation of the global cosmetic market underscores that consumers now demand more than just ingredient names; they seek scientific proof of efficacy. Brands increasingly look for partners with differentiated technologies and solid data. This shift creates new opportunities within the domestic cosmetic ingredient industry, enabling companies like Trienbio to meet the evolving demands for advanced bio-materials.

The revelations from in-cosmetics Korea 2026 confirm that the market's evolution hinges on bio-technology and scientific validation. Trienbio’s commitment to plant-derived PDRN, exosomes, and hybrid oleosomes reflects a forward-thinking approach, indicating that future competitiveness in the beauty industry will be driven not by the mere presence of innovative ingredients but by the corroboration of their effectiveness through technology and data.